SSEA-3 Inhibitors
SSEA-3 inhibitors comprise a diverse group of chemicals that exert their effects either directly on SSEA-3 or indirectly through modulation of key signaling pathways. These inhibitors target specific cellular processes, influencing SSEA-3 expression and function in intricate ways. A prominent example is A83-01, which inhibits the TGF-β type I receptor ALK5, disrupting canonical TGF-β signaling pathways. This disruption indirectly modulates SSEA-3, as the protein is downstream of TGF-β pathways in certain cellular contexts. Similarly, LY2157299, a selective TGF-β receptor type I kinase inhibitor, attenuates TGF-β signaling, impacting SSEA-3 expression. MEK inhibitors such as PD0325901 and U0126 interfere with the MAPK/ERK pathway, affecting SSEA-3 through altered phosphorylation events downstream of MAPK/ERK signaling. Additionally, inhibitors like LY294002 and Wortmannin disrupt the PI3K/Akt pathway, indirectly influencing SSEA-3 as the protein participates in processes regulated by this pathway. SB431542, a selective inhibitor of ALK5, modulates TGF-β signaling and subsequently impacts SSEA-3 expression.
Axitinib, a receptor tyrosine kinase inhibitor, influences SSEA-3 by targeting VEGFRs connected to signaling pathways involving SSEA-3. Other inhibitors like SB203580, Rapamycin, SP600125, and BIRB 796 target p38 MAPK, mTOR, JNK, and specific kinases, respectively, impacting SSEA-3 through intricate signaling cascades. In summary, SSEA-3 inhibitors encompass a spectrum of chemicals that intricately modulate SSEA-3 expression and function either directly or indirectly through precise targeting of signaling pathways. This detailed understanding of their biochemical interactions provides valuable insights for researchers studying SSEA-3 and its regulatory mechanisms in various cellular contexts.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
A 83-01 | 909910-43-6 | sc-203791 sc-203791A | 10 mg 50 mg | $202.00 $811.00 | 16 | |
A83-01 inhibits the TGF-β type I receptor ALK5, attenuating the canonical TGF-β signaling pathway. By impeding TGF-β-mediated processes, it indirectly inhibits SSEA-3, as the protein is modulated downstream of TGF-β pathways in certain contexts. | ||||||
LY2157299 | 700874-72-2 | sc-391123 sc-391123A | 5 mg 10 mg | $213.00 $359.00 | 3 | |
LY2157299 acts as a selective TGF-β receptor type I kinase inhibitor, disrupting TGF-β signaling cascades. Through its impact on the TGF-β pathway, it can indirectly inhibit SSEA-3 expression and function, as SSEA-3 is known to respond to TGF-β signaling in specific cellular contexts. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 inhibits PI3K, a key player in the PI3K/Akt pathway. By disrupting this pathway, LY294002 indirectly influences SSEA-3, as the protein is part of cellular processes regulated by PI3K/Akt signaling. The downstream effects of PI3K inhibition contribute to the modulation of SSEA-3 in specific cellular contexts. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB431542 is a selective inhibitor of the TGF-β type I receptor ALK5, disrupting TGF-β signaling. This inhibition indirectly affects SSEA-3, as the protein is modulated downstream of TGF-β pathways in certain cellular contexts. The altered TGF-β signaling contributes to the inhibition of SSEA-3 expression and function. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin inhibits PI3K, a crucial component of the PI3K/Akt pathway. Through disruption of this pathway, Wortmannin indirectly influences SSEA-3, as the protein is involved in cellular processes regulated by PI3K/Akt signaling. The downstream effects of PI3K inhibition contribute to the inhibition of SSEA-3 in specific cellular contexts. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAPK, impacting the p38 MAPK signaling pathway. By inhibiting this pathway, SB203580 indirectly influences SSEA-3 expression and function, as the p38 MAPK pathway intersects with signaling cascades involving SSEA-3. The altered phosphorylation events downstream of SB203580 contribute to the modulation of SSEA-3 in certain cellular contexts. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, a key component of the mTOR signaling pathway. Through mTOR inhibition, Rapamycin indirectly influences SSEA-3, as the protein is part of cellular processes regulated by mTOR signaling. The downstream effects of mTOR inhibition contribute to the inhibition of SSEA-3 in specific cellular contexts. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a selective inhibitor of JNK, impacting the JNK signaling pathway. By inhibiting this pathway, SP600125 indirectly influences SSEA-3 expression and function, as the JNK pathway intersects with signaling cascades involving SSEA-3. The altered phosphorylation events downstream of SP600125 contribute to the modulation of SSEA-3 in certain cellular contexts. | ||||||
Doramapimod | 285983-48-4 | sc-300502 sc-300502A sc-300502B | 25 mg 50 mg 100 mg | $149.00 $281.00 $459.00 | 2 | |
Doramapimod is a selective inhibitor of p38 MAPK, affecting the p38 MAPK signaling pathway. Through inhibition of this pathway, BIRB 796 indirectly influences SSEA-3 expression and function, as the p38 MAPK pathway intersects with signaling cascades involving SSEA-3. The altered phosphorylation events downstream of BIRB 796 contribute to the modulation of SSEA-3 in specific cellular contexts. | ||||||